Skip to Content
Merck
CN

F9181

Anti-FRAT1 (C-terminal region) antibody produced in rabbit

~1.5 mg/mL, affinity isolated antibody, buffered aqueous solution

Synonym(s):

Anti-Frequently rearranged in advanced T-cell lymphomas, Anti-GBP, Anti-GSK-3 binding protein

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

NACRES:
NA.41
UNSPSC Code:
12352203
Conjugate:
unconjugated
Clone:
polyclonal
Application:
WB
Citations:
8
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


biological source

rabbit

Quality Segment

conjugate

unconjugated

antibody form

affinity isolated antibody

antibody product type

primary antibodies

clone

polyclonal

form

buffered aqueous solution

mol wt

antigen ~29 kDa

species reactivity

human

concentration

~1.5 mg/mL

technique(s)

western blot: 1-2 μg/mL using HEK-293T cell lysate expressing human FRAT1

UniProt accession no.

shipped in

dry ice

storage temp.

−20°C

Gene Information

human ... FRAT1(10023)

General description

FRAT1 (frequently rearranged in advanced T-cell lymphomas-1) is a GSK3β binding protein consisting of a conserved GSK3β interacting domain. In human two FRAT genes have been identified, FRAT1 and FRAT2 whereas FRAT1-3 have been identified in mouse.

Application

Anti-FRAT1 (C-terminal region) antibody is suitable for western blot at a concentration of 1-2μg/mL using rat liver extract (S1 fraction) and a HEK-293T cell lysate expressing human FRAT1.

Biochem/physiol Actions

By inhibiting GSK-3-mediated phosphorylation of β-catenin, FRAT1 plays a major role in the wnt-signaling pathway. During binding to the GSKβ3, it competes with axin and thus displacing GSKβ3 from the axin-β-catenin complex. In the canonical wnt signaling pathway, FRAT1 acts more efficiently than FRAT2. FRAT1 has correlation with clinicopathologic features. It has been reported that in several human malignant tumors, FRAT is overexpressed. It′s upregulated expression have been found in several human cancer lines such as gastric cancers and esophageal squamous cell carcinoma (ESCC).

Physical form

Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.


Still not finding the right product?

Try our Product Selector Tool to narrow your options


Regulatory Information

新产品

This item has



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library


Related Content

Instructions